Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 10/20 | 0.46 |
| ▸ | ADH1B | P00325 | 2/20 | 0.40 |
| ▸ | ADH1C | P00326 | 2/20 | 0.40 |
| ▸ | ADH1A | P07327 | 2/20 | 0.40 |
| ▸ | ADH7 | P40394 | 2/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668300 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL41714 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL8421553 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL668098 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL5508330 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL15171894 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Hydrochloric Acid SCHEMBL2364220 | 0.97 | TSHR (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL7776706 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL5504517 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL7777014 | 0.97 | EPHX1 (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740613-B1 | PROCESS FOR MAKING PAPER WITH IMPROVED FILLER RETENTION AND OPACITY WHILE MAINTAINING WET TENSILE STRENGTH | SOLENIS TECH LP (US) | 2023-07-26 | — | — | EP | claimed |
| US-5840977-A | CYCLOHEXANOL UREA DERIVATIVE AS INTERMEDIATE | FUJIREBIO INC. (JP) | 1998-11-24 | — | — | US | claimed |
| EP-0612740-A1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO Inc. (JP) | 1994-08-31 | — | — | EP | claimed |
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-18 | — | — | US | disclosed |
| US-20240231230-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM | NISSAN CHEMICAL CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20230399292-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | PTC Innovations, LLC | 2023-12-14 | — | — | US | disclosed |
| US-20230399291-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | PTC INNOVATIONS LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-11786493-B2 | Anesthetic compounds and methods of making and using same to treat or prevent pain symptoms | PTC Innovations, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-0612740-B1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO KK (JP) | 1999-09-22 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| US-5840977-A | CYCLOHEXANOL UREA DERIVATIVE AS INTERMEDIATE | FUJIREBIO INC. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
| US-5719298-A | REACTING PANTOTHENIC ACID ACETONIDE WITH UREA COMPOUND IN THE PRESENCE OF ACYLATING AGENT | FUJIREBIO INC. (JP) | 1998-02-17 | — | — | US | disclosed |
| EP-0623578-B1 | Process for the preparation of dichloroacetylchloride | HOECHST AG (DE) | 1997-08-13 | — | — | EP | disclosed |
| US-5433831-A | Process for the preparation of dichloroacetyl chloride | HOECHST AKTIENGESELLCHAFT (DE) | 1995-07-18 | — | — | US | disclosed |
| EP-0623578-A1 | Process for the preparation of dichloroacetylchloride | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-09 | — | — | EP | disclosed |
| EP-0612740-A1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO Inc. (JP) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399292-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | OPRM1, OPRL1, OPRK1 | TSHR 1465/4885ALDH1A1 676/4885EPHX1 204/4885 |
| US-20230399291-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | CHRM2, RXFP2, OPRM1 | TSHR 2336/4885ALDH1A1 1968/4885EPHX1 404/4885 |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SLC5A1, SLC5A2, SLC10A1 | TSHR 3176/4885ALDH1A1 449/4885EPHX1 3381/4885 |
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | TSHR 4810/4885ALDH1A1 1478/4885EPHX1 532/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | TSHR 1050/4885ALDH1A1 4548/4885EPHX1 4127/4885 |
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | BRIX1, TP53, XPOT | TSHR 2641/4885ALDH1A1 1975/4885EPHX1 3315/4885 |
| US-11786493-B2 | Anesthetic compounds and methods of making and using same to treat or prevent pain symptoms | OPRM1, OPRL1, OPRK1 | TSHR 2657/4885ALDH1A1 409/4885EPHX1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.